164 related articles for article (PubMed ID: 38853641)
1. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.
Goulart H; Masarova L; Mesa R; Harrison C; Kiladjian JJ; Pemmaraju N
Br J Haematol; 2024 Jun; ():. PubMed ID: 38853641
[TBL] [Abstract][Full Text] [Related]
2. Myeloproliferative neoplasms in adolescents and young adults.
Amerikanou R; Lambert J; Alimam S
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101374. PubMed ID: 36333071
[TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative Neoplasms in Children.
Hofmann I
J Hematop; 2015 Sep; 8(3):143-157. PubMed ID: 26609329
[TBL] [Abstract][Full Text] [Related]
4. Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms.
Büttner-Herold M; Sticht C; Wiech T; Porubsky S
Histopathology; 2021 Apr; 78(5):738-748. PubMed ID: 33078472
[TBL] [Abstract][Full Text] [Related]
5. Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology.
Chia YC; Siti Asmaa MJ; Ramli M; Woon PY; Johan MF; Hassan R; Islam MA
Diagnostics (Basel); 2023 Jan; 13(1):. PubMed ID: 36611455
[TBL] [Abstract][Full Text] [Related]
6. How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
Robinson SE; Harrison CN
Br J Haematol; 2020 May; 189(4):625-634. PubMed ID: 32150650
[TBL] [Abstract][Full Text] [Related]
7. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
8. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
[TBL] [Abstract][Full Text] [Related]
9. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
Liisborg C
Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
[TBL] [Abstract][Full Text] [Related]
10. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
11. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
12. Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis.
Singh NR
Transl Pediatr; 2015 Apr; 4(2):107-15. PubMed ID: 26835366
[TBL] [Abstract][Full Text] [Related]
13. Morphology of myeloproliferative neoplasms.
Ng ZY; Fuller KA; Mazza-Parton A; Erber WN
Int J Lab Hematol; 2023 Jun; 45 Suppl 2():59-70. PubMed ID: 37211431
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges.
Singh S; Kaur K; Paul D; Jain K; Singh J; Narang V; Garg B; Sood N; Dhillon B
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e569-e578. PubMed ID: 33757770
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
O'Sullivan J; Mead AJ
Adv Biol Regul; 2019 Jan; 71():55-68. PubMed ID: 30528537
[TBL] [Abstract][Full Text] [Related]
16. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
17. Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review.
Al-Mashdali AF; Aldapt MB; Rahhal A; Hailan YM; Elhakeem I; Ali EA; Rozi W; Yassin MA
Diagnostics (Basel); 2023 Jan; 13(3):. PubMed ID: 36766480
[TBL] [Abstract][Full Text] [Related]
18. Mutations in myeloproliferative neoplasms - their significance and clinical use.
Schischlik F; Kralovics R
Expert Rev Hematol; 2017 Nov; 10(11):961-973. PubMed ID: 28914569
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenesis of the myeloproliferative neoplasms.
Greenfield G; McMullin MF; Mills K
J Hematol Oncol; 2021 Jun; 14(1):103. PubMed ID: 34193229
[TBL] [Abstract][Full Text] [Related]
20. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
